Answer
No. It combines a GnRH receptor antagonist with oestrogen–progestogen add-back therapy and is licensed for fibroids and endometriosis, not menopausal hormone replacement.
Sources for this answer
- Ryeqo 40mg/1mg/0.5mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.